Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients

Atherosclerosis

Volumn 183, Issue 2, 2005, Pages 293-300

  Corsetti, James P ^a   Zareba, Wojciech ^b   Moss, Arthur J ^b   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

BMI; Fibrinogen; Glucose; Metabolic syndrome; PAI 1; Postinfarction; Triglyceride

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BODY MASS; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SCREENING; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 27644505610     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.03.046     Document Type: Article

References (25)

1. M.P. Reilly, and D.J. Rader The metabolic syndrome - more than the sum of its parts Circulation 108 2003 1546 1551
2. A.J. Moss, R.E. Goldstein, and V.J. Marder Thrombogenic factors and recurrent coronary events Circulation 99 1999 2517 2522
3. J.P. Corsetti, W. Zareba, and A.J. Moss Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients Atherosclerosis 171 2003 351 358
4. J.P. Corsetti, W. Zareba, A.J. Moss, and C.E. Sparks Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome Atherosclerosis 177 2004 367 373
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):101-12.
6. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855-67.
7. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-67.
8. S.M. Haffner Insulin resistance, inflammation, and the prediabetic state Am J Cardiol 92 Suppl. 2003 18J 26J
9. S.M. Haffner Pre-diabetes, insulin resistance, inflammation and CVD risk Diabetes Res Clin Pract 61 2003 S9 S18
10. M.P. Stern Diabetes and cardiovascular disease. The "Common Soil" hypothesis Diabetes 44 1995 369 374
11. S.M. Haffner, L. Mykkanen, A. Festa, J.P. Burke, and M.P. Stern Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects Circulation 101 2000 975 980
12. Festa A, Hanley AJG, Tracy RP, D'Agosino R, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003;108(15):1822-30.
13. H. Hauner Insulin resistance and the metabolic syndrome - a challenge of the new millennium Eur J Clin Nutr 56 Suppl. 1 2002 S25 S29
14. H.E. Resnick, J. Henderson, and K. Jones Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians Diabetes Care 26 2003 861 867
15. C.J. Lyon, and W.A. Hsueh Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease Am J Med 115 8A 2003 62S 68S
16. I. Juhan-Vague, M.C. Alessi, A. Mavri, and P.E. Morange Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk J Thromb Haemostasis 1 2003 1575 1579
17. A. Mavri, M.C. Alessi, and I. Juhan-Vague Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases J Int Med 255 2004 448 456
18. I. Mertens, and L.F. Van Gaal Obesity, haemostasis and the fibrinolytic system Obes Rev 3 2002 85 101
19. A. Hamsten, U. Faire, and G. Walldius Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 2 1987 3 9
20. K. Malmberg, P. Bavenholm, and A. Hamsten Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age J Am Coll Cardiol 24 1994 592 599
21. P. Bavenholm, U. de Faire, and C. Landou Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function Eur Heart J 19 1998 402 410
22. B. Wiman, T. Andersson, and J. Hallqvist Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the stockholm heart epidemiology program (SHEEP) study Arterioscler Thromb Vasc Biol 20 2000 2019 2023
23. E.A.H. Sims Are there persons who are obese, but metabolically healthy? Metabolism 50 12 2001 1499 1504
24. G.M. Reaven Importance of identifying the overweight patient who will benefit the most by losing weight Ann Intern Med 138 2003 420 423
25. A.D. Karelis, D.H. St-Pierre, F. Conus, R. Rabasa-Lhoret, and E.T. Poehlman Metabolic and body composition factors in subgroups of obesity: what do we know J Clin Endocrinol Metab 89 2004 2569 2575